Sequenom Shares Rise on Upgrade | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom's shares were up 19 percent in Tuesday afternoon trade after investment bank Lazard Capital Markets upgraded the stock to "buy" from "hold."

Sean Lavin, an analyst for Lazard who covers the firm, issued a research note today upgrading the rating and increasing the price target on Sequenom's shares to $13.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.